热门资讯> 正文
SESEN表示，重新提交膀胱癌治疗Vicineum生物制品许可证申请的难度更大；股价下跌
2021-12-10 16:10
09:26 AM EST, 12/09/2021 (MT Newswires) -- Sesen Bio (SESN) said Thursday that after its clinical type A meeting on Dec. 8 with the US Food and Drug Administration it has "greater clarity" on the requirements for resubmission of the biologics license application and the trial design for its bladder cancer treatment Vicineum.
The company said it expects to hold a type C meeting with the FDA in early 2022 to discuss the additional clinical trial.
Sesen shares were down about 20% on Thursday before the open.
Price: 0.87, Change: -0.21, Percent Change: -19.54
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
